# NRC Health share price today (NRC Health, NRC)

> NRC Health's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. NRC · Healthcare · Health Information Services · data as of 4 November 2026. Page: https://www.sectoralpha.in/us/stocks/nrc

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Getting worse, from the last 12 quarters
- Price: $27.07 (+84.1% in a year)
- P/E: 101.0×, over 1 year
- Revenue (Jun 2026): $35.4 M (+4.0% on a year ago)
- Profit (Jun 2026): −$3.3 M
- Operating margin: −0.2% (−24.4 points on a year ago)
- ROE: 81%, FY25
- ROIC: 14.6%, against a 5.2% cost of capital: +9.4 points

The main question: the share price moved +84.1% in a year while yearly earnings per share moved −51.9%. The difference came from the market paying a higher multiple. ## What is the NRC Health share price today? NRC Health's share price was $27.07 at the close on 4 November 2026. That is 40.8% above its average price over the last 200 trading days. In the last 52 weeks it traded between $12 and $27, and at that close it was at the high of that range. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 3 weeks in a row. Over the last 1 year the share price moved +70% while the S&P 500 moved +23%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does NRC Health pay? NRC Health paid $0.60 per share over the last four reported quarters. The most recent declaration was $0.16 for Jun 2026. At today's price of $27.07 that is a yield of 2.22%, based on dividends already paid, not a forecast. ## Which stock lists is NRC Health on? NRC Health is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is NRC Health profitable? NRC Health posted a net loss of $3.3 M in the Jun 2026 quarter. Full-year FY25 profit was $11.3 M. Over 4 years profit has grown −25.9% a year on average. That loss is 9.3% of the quarter's revenue. The same quarter a year earlier lost $190 K. 2 of the last 12 reported quarters were loss-making. For the full year, FY25 profit was $11.3 M (−54.4% on the year before). On average over the last four quarters, profit changed −50.3% and revenue −0.1%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does NRC Health make, and is it growing? NRC Health reported $35.4 M of revenue in the Jun 2026 quarter, +4.0% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 4 years it has grown −1.8% a year on average. The last full year, FY25, came in at $137 M. The last four reported quarters add to $140 M. Recent pace: the last four quarters grew −0.1% on average, against −1.8% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −0.2%, against −2.2% a year over the last 8 quarters (stabilising); profit over the last 12 months grew −69.4%, against −56.8% a year (rolling over). ## How much of every $100 of sales does NRC Health keep? NRC Health's operating margin was −0.2% in the Jun 2026 quarter, 24.4 percentage points lower than the same quarter a year ago. Across 5 years it has been between 21.4% and 34.3%. The latest quarter is below every full year in that period. Why the margin moved: operating margin changed −24.4 percentage points on the year while gross margin changed −0.2 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is NRC Health's profit turning into cash? Over the last 3 years, 148% of NRC Health's reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $26.5 M of operating cash against $11.3 M of profit. After $10.7 M of spending on assets, $15.7 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does NRC Health's cash go? NRC Health does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $41.9 M on assets over the last 3 years. Averaged over those years that is 10.2% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $41.9 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is NRC Health's P/E ratio, and how does it compare with its own history? NRC Health's P/E is 101.0×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved −51.9% while the price moved +84.1%. The price did better than earnings, which pushed the multiple up within its own range. In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple. ## Is the NRC Health business getting better or worse? NRC Health's business is getting worse. Revenue, profit and EPS growth are shrinking: revenue growth is −0.2% in the latest quarter, against −0.2% at its best in 12 quarters, with ROCE falling at 23.8%. This is based on 12 quarters of 4 measures. Why it matters: falling lines mean any ratio below that looks low should be read with that direction in mind. ## How much does NRC Health earn on its capital? NRC Health earned a ROE of 81% in FY25. That is up from a low of 44% in FY21. Its return on capital used (ROIC) is 9.4 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 8.2% net margin and 1.02× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 8.2% net margin × 1.02× asset turnover × 9.64× leverage (assets divided by equity) ≈ 80.6% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 14.6% − 5.2% = +9.4 percentage points. The 5.2% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value. The 14.6% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 21.0%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does NRC Health have too much debt? NRC Health has total debt of $90.4 M against shareholder equity of $6.5 M as of Jun 2026, so its debt is 13.81× its equity. Year by year, that ratio went from 0.34 in FY21 to 5.74 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the NRC Health shareholding pattern? 6.7% of NRC Health's tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 6.3 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is NRC Health from balance-sheet trouble? For NRC Health, the Z-score is 2.85. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the grey area between the two. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 2.85 is in the grey area, neither clearly safe nor clearly in trouble. ## How does NRC Health rank in its industry? 52.1 out of 100, rank 8 of 29 in Health Information Services, with 64% of the evidence available. NRC Health scores 52.1 out of 100 against the 29 companies it is compared with in Health Information Services, ranking 8. Relative strength against the index is 33.8%, and revenue and profit growth are weak. The four parts add up to the total exactly: 9.6 + 18.4 + 9.7 + 14.4 = 52.1. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is NRC Health compared with? NRC Health ranks 8 of 29 Health Information Services companies on the 4-Factor Sector Score, with 52.1 out of 100. 1. [Hinge Health, Inc.](https://www.sectoralpha.in/us/stocks/hnge) HNGE · leader · Most evidence points up · 64% evidence 72.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.5/35 · Revenue 49.7% · Profit n/a · Operating margin change 436.5 points · 62% evidence Capital efficiency 19.0/25 · ROCE 27.1% · Operating margin 19% · 76% evidence Valuation 9.3/20 · P/E 59.8× · PEG n/a · 15% evidence Relative strength 17.3/20 · Lead over its industry 40.2% · Lead over S&P 500 78.7% · 1 year 171.7% · 100% evidence · 12 of 12 weeks ahead Exact sum: 26.5 + 19 + 9.3 + 17.3 = 72.1 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Veeva Systems Inc.](https://www.sectoralpha.in/us/stocks/veev) VEEV · breaking out · Most evidence points up · 85% evidence 68.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.9/35 · Revenue 16.5% · Profit 25.2% · Operating margin change 0.9 points · 95% evidence Capital efficiency 18.8/25 · ROCE 13.6% · Operating margin 29.6% · 76% evidence Valuation 13.0/20 · P/E 32.6× · PEG 1.3 · 65% evidence Relative strength 16.1/20 · Lead over its industry 4% · Lead over S&P 500 34.9% · 1 year 5.3% · 100% evidence · 12 of 12 weeks ahead Exact sum: 20.9 + 18.8 + 13 + 16.1 = 68.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [HeartFlow, Inc.](https://www.sectoralpha.in/us/stocks/htfl) HTFL · leader · Evidence leans up · 61% evidence 57.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 43.2% · Profit n/a · Operating margin change 3.7 points · 62% evidence Capital efficiency 4.5/25 · ROCE -24.2% · Operating margin -27.9% · 76% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 19.0/20 · Lead over its industry 22.7% · Lead over S&P 500 57.9% · 1 year 73.7% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24 + 4.5 + 10 + 19 = 57.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Waystar Holding Corp.](https://www.sectoralpha.in/us/stocks/way) WAY · breaking out · Evidence leans up · 81% evidence 56.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.7/35 · Revenue 19.4% · Profit 58.8% · Operating margin change 0.4 points · 83% evidence Capital efficiency 12.2/25 · ROCE 5.2% · Operating margin 24.4% · 76% evidence Valuation 15.6/20 · P/E 29.2× · PEG 0.64 · 65% evidence Relative strength 8.7/20 · Lead over its industry -18.4% · Lead over S&P 500 7.6% · 1 year -18% · 100% evidence · 11 of 12 weeks ahead Exact sum: 19.7 + 12.2 + 15.6 + 8.7 = 56.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Schrödinger, Inc.](https://www.sectoralpha.in/us/stocks/sdgr) SDGR · leader · Evidence leans up · 64% evidence 55.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.0/35 · Revenue 8.8% · Profit n/a · Operating margin change 26 points · 62% evidence Capital efficiency 4.6/25 · ROCE -32.9% · Operating margin -70.6% · 76% evidence Valuation 11.2/20 · P/E -22.3× · PEG n/a · 15% evidence Relative strength 18.9/20 · Lead over its industry 22.7% · Lead over S&P 500 57.8% · 1 year 60.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21 + 4.6 + 11.2 + 18.9 = 55.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [HealthEquity, Inc.](https://www.sectoralpha.in/us/stocks/hqy) HQY · turning · Evidence leans up · 85% evidence 54.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue 7.4% · Profit 62.3% · Operating margin change 0.5 points · 95% evidence Capital efficiency 16.1/25 · ROCE 11.4% · Operating margin 28.4% · 76% evidence Valuation 11.6/20 · P/E 35.6× · PEG 1.53 · 65% evidence Relative strength 5.8/20 · Lead over its industry -14.5% · Lead over S&P 500 12.5% · 1 year 16.1% · 100% evidence · 5 of 12 weeks ahead Exact sum: 21.4 + 16.1 + 11.6 + 5.8 = 54.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Doximity, Inc.](https://www.sectoralpha.in/us/stocks/docs) DOCS · breaking out · Evidence leans up · 81% evidence 53.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 11.5/35 · Revenue 11.2% · Profit -28.6% · Operating margin change -16.3 points · 83% evidence Capital efficiency 20.9/25 · ROCE 21.6% · Operating margin 21.5% · 76% evidence Valuation 10.8/20 · P/E 22.7× · PEG 1.74 · 65% evidence Relative strength 10.1/20 · Lead over its industry -16.5% · Lead over S&P 500 9.8% · 1 year -36.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 11.5 + 20.9 + 10.8 + 10.1 = 53.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. NRC Health this page NRC · turning · Evidence leans up · 64% evidence 52.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 9.6/35 · Revenue -0.7% · Profit -68.4% · Operating margin change -24.4 points · 62% evidence Capital efficiency 18.4/25 · ROCE 24.3% · Operating margin -0.2% · 76% evidence Valuation 9.7/20 · P/E 45× · PEG n/a · 15% evidence Relative strength 14.4/20 · Lead over its industry 2.1% · Lead over S&P 500 33.8% · 1 year 84.1% · 100% evidence · 7 of 12 weeks ahead Exact sum: 9.6 + 18.4 + 9.7 + 14.4 = 52.1 · What this means: Relative strength against the index is 33.8%, and revenue and profit growth are weak. 9. [BrightSpring Health Services, Inc.](https://www.sectoralpha.in/us/stocks/btsg) BTSG · turning · Too little evidence to rank firmly · 56% evidence 51.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.0/35 · Revenue n/a · Profit n/a · Operating margin change 1.6 points · 39% evidence Capital efficiency 12.6/25 · ROCE 10.1% · Operating margin 3.4% · 76% evidence Valuation 10.0/20 · P/E 39.7× · PEG n/a · 15% evidence Relative strength 9.0/20 · Lead over its industry -2.5% · Lead over S&P 500 27.6% · 1 year 110.6% · 100% evidence · 2 of 12 weeks ahead Exact sum: 20 + 12.6 + 10 + 9 = 51.6 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 10. [Phreesia, Inc.](https://www.sectoralpha.in/us/stocks/phr) PHR · turning · Evidence leans down · 67% evidence 49.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.7/35 · Revenue 12.7% · Profit n/a · Operating margin change 7.2 points · 71% evidence Capital efficiency 9.5/25 · ROCE 4.3% · Operating margin 5.9% · 76% evidence Valuation 9.0/20 · P/E 63.5× · PEG n/a · 15% evidence Relative strength 6.8/20 · Lead over its industry -24.7% · Lead over S&P 500 -0.6% · 1 year -40.1% · 100% evidence · 8 of 12 weeks ahead Exact sum: 23.7 + 9.5 + 9 + 6.8 = 49 · What this means: Earnings are strong; relative strength in its sector is -24.7% and the one-year return is -40.1%. 11. [Tempus AI, Inc.](https://www.sectoralpha.in/us/stocks/tem) TEM · breaking out · Evidence leans down · 64% evidence 48.5 out of 100 Growth Capital Valuation Relative
12. [Certara, Inc.](https://www.sectoralpha.in/us/stocks/cert) CERT · leader · Evidence leans down · 64% evidence 46.0 out of 100 Growth Capital Valuation Relative
13. [HealthStream, Inc.](https://www.sectoralpha.in/us/stocks/hstm) HSTM · leader · Evidence leans down · 81% evidence 45.6 out of 100 Growth Capital Valuation Relative
14. [Omada Health, Inc.](https://www.sectoralpha.in/us/stocks/omda) OMDA · quiet · Evidence leans down · 64% evidence 45.2 out of 100 Growth Capital Valuation Relative
15. [10x Genomics, Inc.](https://www.sectoralpha.in/us/stocks/txg) TXG · leader · Evidence leans down · 64% evidence 45.2 out of 100 Growth Capital Valuation Relative
16. [American Well Corporation](https://www.sectoralpha.in/us/stocks/amwl) AMWL · losing its lead · Evidence leans down · 61% evidence 45.1 out of 100 Growth Capital Valuation Relative
17. [Spok Holdings, Inc.](https://www.sectoralpha.in/us/stocks/spok) SPOK · turning · Evidence leans down · 81% evidence 44.6 out of 100 Growth Capital Valuation Relative
18. [Omnicell, Inc.](https://www.sectoralpha.in/us/stocks/omcl) OMCL · turning · Evidence leans down · 71% evidence 43.3 out of 100 Growth Capital Valuation Relative
19. [Carlsmed, Inc.](https://www.sectoralpha.in/us/stocks/carl) CARL · leader · Evidence leans down · 61% evidence 43.1 out of 100 Growth Capital Valuation Relative
20. [Teladoc Health, Inc.](https://www.sectoralpha.in/us/stocks/tdoc) TDOC · turning · Evidence leans down · 61% evidence 43.1 out of 100 Growth Capital Valuation Relative
21. [Privia Health Group, Inc.](https://www.sectoralpha.in/us/stocks/prva) PRVA · turning · Evidence leans down · 81% evidence 42.3 out of 100 Growth Capital Valuation Relative
22. [Evolent Health, Inc.](https://www.sectoralpha.in/us/stocks/evh) EVH · turning · Evidence leans down · 64% evidence 38.0 out of 100 Growth Capital Valuation Relative
23. [Claritev Corporation](https://www.sectoralpha.in/us/stocks/ctev) CTEV · quiet · Evidence leans down · 64% evidence 37.4 out of 100 Growth Capital Valuation Relative
24. [SOPHiA GENETICS SA](https://www.sectoralpha.in/us/stocks/soph) SOPH · losing its lead · Evidence leans down · 61% evidence 36.4 out of 100 Growth Capital Valuation Relative
25. [GoodRx Holdings, Inc.](https://www.sectoralpha.in/us/stocks/gdrx) GDRX · losing its lead · Most evidence points down · 81% evidence 34.9 out of 100 Growth Capital Valuation Relative
26. [Simulations Plus, Inc.](https://www.sectoralpha.in/us/stocks/slp) SLP · Too little evidence to rank firmly · 44% evidence 56.3 out of 100 Growth Capital Valuation Relative
27. [Talkspace, Inc.](https://www.sectoralpha.in/us/stocks/talk) TALK · Too little evidence to rank firmly · 44% evidence 48.4 out of 100 Growth Capital Valuation Relative
28. [Weave Communications, Inc.](https://www.sectoralpha.in/us/stocks/weav) WEAV · Too little evidence to rank firmly · 41% evidence 47.7 out of 100 Growth Capital Valuation Relative
29. [TruBridge, Inc.](https://www.sectoralpha.in/us/stocks/tbrg) TBRG · Too little evidence to rank firmly · 31% evidence 42.2 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Health Information Services](https://www.sectoralpha.in/us/sectors/health-information-services), all 29 compared on one page. ## Which companies are close to NRC Health in size? NRC Health is the 22nd largest of 30 Health Information Services companies on Sector Alpha by market value (scores of 4 November 2026). Just above it: Phreesia, Inc., SOPHiA GENETICS SA and Weave Communications, Inc. Just below it: Evolent Health, Inc., Carlsmed, Inc. and TruBridge, Inc. ### Health Information Services companies close in size

1. [Phreesia, Inc.](https://www.sectoralpha.in/us/stocks/phr) $818 million
2. [SOPHiA GENETICS SA](https://www.sectoralpha.in/us/stocks/soph) $593 million
3. [Weave Communications, Inc.](https://www.sectoralpha.in/us/stocks/weav) $592 million
4. NRC Health $574 million
5. [Evolent Health, Inc.](https://www.sectoralpha.in/us/stocks/evh) $543 million
6. [Carlsmed, Inc.](https://www.sectoralpha.in/us/stocks/carl) $439 million
7. [TruBridge, Inc.](https://www.sectoralpha.in/us/stocks/tbrg) $388 million

[All 30 Health Information Services companies, largest first](https://www.sectoralpha.in/us/sectors/health-information-services#all-companies)

### Companies close in size in other industries

1. [Brandywine Realty Trust](https://www.sectoralpha.in/us/stocks/bdn) $515 million · REIT - Office
2. [The York Water Company](https://www.sectoralpha.in/us/stocks/yorw) $514 million · Utilities - Regulated Water
3. NRC Health $511 million
4. [Ethan Allen Interiors Inc.](https://www.sectoralpha.in/us/stocks/etd) $511 million · Furnishings, Fixtures & Appliances
5. [AMTD Digital Inc.](https://www.sectoralpha.in/us/stocks/hkd) $506 million · Software - Application

## What else do people ask about NRC Health? ### What were NRC Health's latest quarterly results? NRC Health reported revenue of $35.4 M and a net loss of $3.3 M for the Jun 2026 quarter. Earnings per share were −$0.15. The operating margin was −0.2%, 24.4 percentage points lower than a year earlier (as of 4 November 2026). ### What is NRC Health's market cap? NRC Health's market capitalisation is $574 M at a stock price of $27.07. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is NRC Health performing? NRC Health's latest readings are below. Over the past 13 weeks it has done better than the S&P 500, for 3 weeks running. This describes what the data did, not a rating (as of 4 November 2026). ### Will NRC Health's stock price go up? This page does not forecast NRC Health's stock price. What it shows instead: the stock price is $27.07. Nobody can reliably say which way a price will move, and this site does not try (as of 4 November 2026). ### Where is NRC Health in its business cycle? NRC Health's FY25 operating margin was 21.4%, against a 5-year range of 21.4% to 34.3%: the low end of its own range, which is often where recoveries start. The latest quarter was −0.2%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the NRC Health story? The main question: the share price moved +84.1% in a year while yearly earnings per share moved −51.9%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is NRC Health a stock worth studying right now? What the numbers show: NRC Health's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). This is research, not advice. We’re not SEBI-registered.